PDCD1 and hepatocellular carcinoma: Antibody-mediated PD-1 or PD-L1 blockade held immense clinical promise for a range of advanced tumors (including non-small cell lung cancer, melanoma, gastroesophageal cancer, hepatocellular carcinoma, and others) in comparison to chemotherapy or palliative care (16–19).